Interferon levels and interferon-stimulated gene expression identify patient subsets with distinct clinical and immunological characteristics in systemic lupus erythematosus - PubMed

5 days ago

Interferon (IFN) system dysregulation in Systemic Lupus Erythematosus (SLE) is a potential therapeutic target.
Study focused on IFN types I, II, and III, alongside interferon-stimulated gene (ISG) expression in SLE patients.
IFNα, IFNγ, and IFNλ3 levels, as well as IFN score, were significantly elevated in SLE patients compared to healthy controls.
IFNα levels and IFN score positively correlated with disease activity.
High IFNα group associated with leukopenia and multiple autoantibodies; high IFNγ group linked with rash.
High IFNλ3 group showed positive association with anti-Ro52 autoantibodies and negative association with low complement.
IFNλ4 levels, though not elevated in SLE, associated with IFN score and anti-dsDNA positivity.
Autoantibody profile-based clustering identified three patient subgroups with distinct IFN levels and disease characteristics.
Findings suggest IFNα levels and IFN score as potential biomarkers for monitoring SLE disease activity.
Comprehensive assessment of IFNs provides insight into IFN pathway dynamics and heterogeneity in SLE.

Hasty Briefsbeta